Co-Diagnostics, Inc. Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $145.4K | — | -$5.9M | — | -$7.0M | -$0.16 |
| Q2 FY202510-Q · 2025-06-30 | $162.9K | — | -$7.7M | — | -$8.1M | -$0.23 |
| Q1 FY202510-Q · 2025-03-31 | $50.3K | — | -$7.5M | — | -$8.6M | -$0.24 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $44.7M | $4.9M | $11.4M | $39.8M |
| Q2 FY202510-Q | $46.5M | $5.3M | $11.1M | -$15.6M |
| Q1 FY202510-Q | $55.1M | $7.2M | $1.9M | -$15.6M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | -$7.0M | -$5.9M | $119.1K | 48,142,582 |
| Q2 FY202510-Q | -$8.1M | -$7.7M | $130.8K | 36,182,468 |
| Q1 FY202510-Q | -$8.6M | -$7.5M | $28.7K | 33,572,643 |
Filings
(4)Methodology
Every figure on this page is pulled directly from Co-Diagnostics, Inc.'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].